literature

IV mutation literature information.

Molecular Characterization of Seasonal Influenza A and B from Hospitalized Patients in Thailand in 2018-2019.

PMID: 34070388 2021 Viruses

Discussion: The sequence analysis of the NA gene reveals one potential NA drug-resistance substitution (V116A) but not other amino acid substitutions such as I117V, Q136K, D151A, Y155H, R156K, D198V, I222R, R224K, Q226H, E227D, E227Q, H274Y, R293K, N294S, E425G, and I436N.

Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.

PMID: 32631440 2020 Virology journal

Result: Other NA drug-resistance substitutions (V116A, I117V, Q136K, D151A, Y155H, R156K, D198V, I222V, R224K, Q226H, E227D, E277Q, R293K, N294S, E425G, and I436N) were not detected.

Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.

PMID: 31783761 2019 Virology journal

Table: Y155H

Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.

PMID: 28951584 2017 Scientific reports

Introduction: discovered a series of diazenylaryl sulfonic acids as NA inhibitors, which inhibited N1 NA with drug-resistant mutations, including H274Y, N294S, Y155H, Q136L, I427Q and I427M.

Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.

PMID: 27659246 2016 Journal of virological methods

Abstract: Employing reverse genetics, a set of influenza virus variants containing an amino acid substitution associated with oseltamivir resistance in N1 isolates (H274Y, N294S, Y155H or Q136L) was generated.

Abstract: For 5-amidino and 5-guanidino analogs of oseltamivir a significantly stronger inhibition of virus variants carrying a NA-H274Y was confirmed, and additionally shown for NA-N294S and NA-Y155H substitutions as compared to the parent compound.

Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.

PMID: 25701593 2015 Antiviral research

Method: (accessed 10/23/2014) were screened for the presence of known molecular markers (N2 numbering) of NAI resistance that demonstrated clinical relevance in human influenza A viruses of N1 (D198N, I222R, H274Y, N294S) or N2 (E119V, R292K, N294S) subtypes, and for NA markers reported in surveillance studies or in recombinant viruses of N1 (V116A, I117V, E119V, Q136L/K, V149A, Y155H, I222V/M/K,

Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.

PMID: 25033052 2014 Euro surveillance

Abstract: Contrary to what was observed in the seasonal A(H1N1) viruses, neither of the Y155H A(H1N1) pdm09 viruses described here showed a phenotype of reduced inhibition by NAIs as determined by the neuraminidase enzyme inhibition assay (MUNANA).

Abstract: During the 2012/13 epidemic season in Spain, two A(H1N1) pdm09 viruses bearing the specific Y155H substitution in the NA were detected and isolated from two patients diagnosed with severe respiratory syndrome and pneumonia requiring admission to the intensive care unit.

Abstract: High-throughput sequencing of the NA of both Y155H viruses showed that they were composed to >99

Browser Board

Co-occurred Entities

Filtrator